The American Diabetes Association CEO apologizes to five members kicked out of annual convention for distributing protest literature, launches review of what went awry.

Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.

Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.

Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.

A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.

A stem cell-based heart patch improved pumping in a small trial for advanced heart failure. "Very good first step," researcher says.

Inside the longevity conference that brings together founders, investors, biohackers, and the generally death-averse to discuss how to forestall — or even beat — our demise.

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.

Growing evidence suggests it takes a sustained viral infection in the right genetic environment to lead to type 1 diabetes.

Nine states have been pursuing the idea of prescription drug affordability boards. Maryland's board just set limits on the price of Ozempic.

The White House nods to medication-assisted treatment and fentanyl test strips, despite recently placing new limits.

A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.

A few transplant patients in a small study were able to stop using immunosuppressive drugs, thanks to pre-transplant cell therapy.

The inflammatory bowel disease therapy succeeded in its first major testing, setting up a competition with several large drugmakers.

The EPA names microplastics as a potential drinking water contaminant, a move that is seen as an appeal to Kennedy's MAHA movement.

A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen inequities in accessing treatment.

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney disease known as IgA nephropathy.

Xenon Pharmaceuticals said its treatment for a common type of seizure disorder significantly reduced the frequency of those seizures compared to a placebo.

How a remote patient monitoring company is reworking its tech to enroll in a Medicare program seeking to align payment with health care outcomes.

Casey Means, now the epitome of a “MAHA mom," invokes motherhood and “wholeness” in health in making her case to be the U.S. surgeon general.

New treatment approaches could give inflammatory bowel disease patients hope, and make drugmakers a bonanza.

The smaller arteries of women means a little plaque can be more dangerous than it is for men.

Realfood.gov now features a chatbot tool that’s Elon Musk-affiliated — and rather skeptical of some MAHA initiatives.